We recently published a list of the 10 best mid -cap biotech shares to buy. In this article we will see where Ultragenyx Pharmaceutical Inc. (Nasdaq: weird) stands against the other best mid -cap biotech shares to buy.
On March 6, Jared Holz, Mizuho Health Care Equity Strategist, appeared on BHMNews’s ‘Power Lunch’ to discuss that investing in Biotech and the oversaturation in the sector. He said we look at the name of biotech shares on the public market, we are on the 700-800 series, depending on the day. Almost a quarter of these have business values in negative territory. That in fact means that investors and companies have exhausted options in some respects. To create each value, it is necessary to shift the focus and to come up with another attack plan by an active one that they do not currently possess and resuscitate the company.
In some respects, investors and analysts are always looking for a clear path for biotech as a sector to perform better. However, Holz said that we are in a difficult place if a quarter of the index is filled with companies with more cash than market capitalization. That is why he suggested, which some people consider somewhat hyperbolic, get away from the tail, because there are too many assets.
Thousands of biotech companies compete against each other for small market or sales opportunities. Holz was of the opinion that venture funds should stop making so many companies that will replace each other in a few years. It would be useful to resolve all biotech shares with negative values and to return the money to shareholders.
Also read: 12 best diagnostic shares to invest now and 7 most undervalued biotech shares to invest.
Biotechs are a seductive scenario, because the shares of a company can be worth $ 5 with a potentially blockbuster medication in the pipeline that could even cure cancer. The shares of the company can rise to hundreds of dollars if the clinical test succeeds. At the same time, however, it can fall to $ 0 if the test does not do. Holz therefore says that the sector is incredibly seductive, and thousands of investors put their career on the line every day to try to find this out.
He characterized Biotech as one of the few sectors in all the shares where Single Stock Picking is the only way to make money. Building on his many years of experience for industry, he said that the index has hardly emerged since the past decade. It has essentially been flat. In the meantime, any other index that one can find has doubled or more. That is why there is a clear problem with the wider complex. But if you find the right one, you can kill it in the sector.
We have sieved through stock screeners, financial media reports and ETFs to put together a list of 30 biotech shares with a market capitalization between $ 2 billion and $ 10 billion. We then selected the top 10 with the highest number of holders of hedge funds, from Q4 2024, and ranked in rising order. We have purchased the hedge fund sentiment data from the Insider Monkey database.
Why are we interested in the shares that stack hedge funds? The reason is simple: our research has shown that we can surpass the market by imitating the best share choices of the best hedge funds. The strategy of our quarterly newsletter selects 14 CAP and Large-CAP shares every quarter and has returned 373.4% since May 2014 and has reported its benchmark with 218 percentage points (See more details here).
A research team in a laboratory leads through microscopes with a biological product.
Market capitalization: $ 3,58 billion
Number of holders of hedge funds: 57
Ultragenyx Pharmaceutical Inc. (Nasdaq: weird) develops, acquires and commercializes new products to treat genetic diseases. The product portfolio includes Crysvita, Mepsevii, Dojolvi and Evkeeza. In 2024, the company expanded its company through four products in five indications worldwide.
Ultragenyx Pharmaceutical Inc. (Nasdaq: Strange) is planning to expand its commercial company base in 2025, supported by various products in launching mode worldwide. The company sets this progress on its way to GAAP’s profitability in 2027. It also exceeded expectations with its 2024 results and reported a total turnover of $ 560 million. The company expects the total turnover of 2025 to be between $ 640 million and $ 670 million.
Piper Sandler analyst Allison Bratzel retained a buy -rating on Ultragenyx Pharmaceutical Inc. (Nasdaq: Strange) on March 17 and set a target of $ 115.00. JP Morgan analyst Anupam Rama also maintained a buy -rating for the company on 6 March, which sets a price target of $ 104.00. Analysts are bullish in the field of shares and the median price target of $ 38.69 implies an advantage of 124.86% compared to the current level.
Baron Health Care Fund stated the following with regard to Ultragenyx Pharmaceutical Inc. (Nasdaq: weird) in his Q3 2024 investor letter:
“We have purchased Ultragenyx Pharmaceutical Inc. (Nasdaq: weird), a biopharmaceutical company focused on developing treatments for rare genetic diseases. The company has impressively approved 4 medicines in 5 indications in 10 years in 10 years, we are the most enthusiasm clinical in the Late-Stadium of the company of the Late-Stadium of the company of the Late-Stadium of the Late-Stadium of the Late-Stadium of the Late-Stadium of the Late-Stadium of the Op. Product pipeline. Genetic condition that ensures that the buyer accumulates in the body, where we will soon receive proof-of-concept data. We think that each of these programs has potential for creating a significant value, so that the company is transformed into one with considerably higher income and profit. “
Generally rare State 3rd On our list of the best mid -cap biotech shares to buy. Although we recognize the potential of rare as an investment, our conviction is the belief that AI shares have a greater promise for supplying a higher efficiency within a shorter period of time. If you are looking for an AI share that is promising than rare, but it acts with less than 5 times the income, view our report on the Cheapest AI stock.
Read next: 20 best AI shares to buy now And 30 best shares to buy now according to billionaires.
Publication: none. This article was originally published on Insider monkey.
